NCT06452771View on ClinicalTrials.gov

A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 27, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

September 30, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

ALN-ANG3

Administered subcutaneous (SC) injection

DRUG

Placebo (PB)

Administered SC injection

Trial Locations (1)

8013

New Zealand Clinical Research, Christchurch

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06452771 - A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults | Biotech Hunter | Biotech Hunter